Where to Buy Ipamorelin: 7 Purity and Identity Checks, and Why Fill Quantity Is the Real Risk

Ipamorelin is the easiest peptide in its class to identify and the one with no legal compounding route. At 711.9 daltons it sits 106 to 175 below every compound it gets confused with, and FDA's advisory committee voted 0–12 against it.

Ipamorelin sits in the growth hormone peptides category and is usually bought as half of a blend. The evidence picture — one randomised trial that missed its endpoint, one 320-patient trial that never reported — is in ipamorelin: the selective secretagogue that failed its only published human trial; this page is about the vial, the certificate and the regulatory position. For per-injection volume there is the CJC-1295 and ipamorelin calculator.

What is ipamorelin, and why does source quality matter?

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH₂, CAS 170851-70-4, formula C₃₈H₄₉N₉O₅, molecular weight 711.9 g/mol, with a human intravenous half-life of about two hours and a single target, the ghrelin receptor GHS-R1a. Source quality matters differently here than elsewhere in this category: at 711.9 daltons ipamorelin sits 106 to 175 daltons below every peptide it is sold beside, so the realistic risks are underfill and non-peptide bulking, not substitution.

Two structural facts drive everything on this page. Ipamorelin carries no Trp-Trp core — the motif shared by GHRP-2, GHRP-6 and hexarelin — using Aib and D-2-naphthylalanine instead, which makes it the chemical outlier of its class rather than a variation on it. And because that different chemistry produces a much smaller molecule, it is the easiest member of the class to confirm by mass. Identity, the check most buying guides lead with, is nearly free on this compound.

What is not free is everything downstream of identity. A vial containing genuine ipamorelin can still contain the wrong amount of it, sitting alongside salts, residual water and non-peptide bulking agents that a purity percentage will not reveal. FDA reached the same conclusion from the opposite direction when it reviewed the compounding submission and called the free base "not well-characterized from the physical and chemical characterization perspective" — missing impurities, aggregates and endotoxin data. That is a quantity-and-contaminant complaint, not an identity complaint.

The ipamorelin compound page carries the current test coverage and vendor spread. What none of it settles is what the compound does, because the human record is one eight-man pharmacokinetic study, one failed randomised trial and one silence.

What is the regulatory status of ipamorelin?

Ipamorelin is not approved anywhere and has no legal compounding route as of August 2026. FDA's Pharmacy Compounding Advisory Committee reviewed it on 29 October 2024 and voted 0 in favour, 12 against, with 1 abstention, on both the free base and the acetate. Ipamorelin acetate remains on FDA's Category 2 list for 503B outsourcing facilities, added 29 September 2023 on immunogenicity and aggregation grounds, with the page current as of 22 April 2026. WADA prohibits it at all times under S2.2.4.

Because no compounding route exists, this page has no compounded-ipamorelin section — there is no pharmacy pathway to compare a research vial against, which is not true of sermorelin or tesamorelin in the same category.

The briefing document behind that vote is unusually direct for a regulatory filing, and three of its findings are purchasing information rather than legal information:

• "FDA has not identified data to support the effectiveness of ipamorelin… for the diagnosis or treatment of GHD."

• "Due to its primary mechanism of action as a ghrelin receptor agonist, ipamorelin… may have behavioral reinforcing properties, which can contribute to development of addiction, and may also negatively affect reproductive health."

• Ipamorelin free base is "not well-characterized from the physical and chemical characterization perspective" — missing impurities, aggregates and endotoxin data.

The direction of travel is what makes this compound's position unusual in 2026, and it runs opposite to most of this cluster. Ipamorelin was not among the substances whose nominations were withdrawn in April 2026, and it was not on the July 2026 PCAC agenda that advanced BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. It stayed on the active list while others moved. "FDA is reconsidering peptides" is true in general and false for this one — a distinction worth holding onto when a seller cites the July 2026 news as though it applied here. Our FDA peptide regulation timeline tracks where each nomination actually stands.

In sport, ipamorelin is named explicitly at S2.2.4 of WADA's 2026 Prohibited List, under growth hormone secretagogues and their mimetics: prohibited at all times, non-specified. That is a named-category prohibition, not an inference from a catch-all clause.

How do you tell ipamorelin from GHRP-2, GHRP-6 and hexarelin?

Any mass spectrometer separates them, including a low-resolution one. Ipamorelin's monoisotopic mass is 711.3857; GHRP-2 sits at 817.4275, GHRP-6 at 872.4446 and hexarelin at 886.4602 — gaps of 106.04, 161.06 and 175.07 daltons. Ipamorelin is also the only member of the group without the Trp-Trp core, using Aib and D-2-naphthylalanine instead, so it is a genuinely different molecule rather than a one-residue variant. No high-resolution instrument is required to see a 106-dalton gap.

Compare that with the discrimination problems elsewhere in the growth hormone category, where sermorelin and Mod GRF (1-29) are ten daltons apart and a rounded nominal mass will not settle which one is in the vial. Ipamorelin has no such problem. A single mass number resolves it against all three of its neighbours at once, which is why an ipamorelin certificate with a purity figure and no identity result is a choice rather than a technical limitation. See mass spectrometry for peptides for what an identity result establishes that a purity percentage cannot.

Be careful about what the confirmation buys you, though, because the class difference that matters to a buyer is not chemical. The three neighbours all raise cortisol, ACTH or prolactin in humans. Ipamorelin's failure to do so was demonstrated in conscious swine, by Raun et al. in 1998, at doses more than 200-fold above its own GH ED₅₀. Confirming you hold ipamorelin rather than GHRP-2 confirms the molecule, not the selectivity advantage — that comparison mixes animal data for one compound with human data for the others. The three-way version of this question is in GHRP-2 vs GHRP-6 vs ipamorelin.

7 things to check before ordering ipamorelin

Seven checks cover ipamorelin, and the order matters more than usual because the check vendors advertise is the one this molecule passes most easily. Mass spectrometry at 711.9 Da, net peptide content, third-party HPLC against a 99.65 benchmark, an LAL endotoxin result that FDA named as missing, the form in the vial, this platform's coverage of that specific shop, and a pricing check across a 7× spread — with an honest account of what none of it establishes.

1. Mass spectrometry at 711.9 Da. Expect 711.3857 monoisotopic, or 712.3929 as the [M+H]⁺ ion. Ask for a batch-matched result rather than a specimen certificate from an earlier lot, which describes a different vial. This is the cheapest check on the list and the one ipamorelin passes most easily, which is precisely why it should not be the last thing you ask for.

2. Net peptide content — the check that matches this compound's actual failure mode. Purity reports the proportion of a sample that is one species; it says nothing about how much of that species is in the vial. Underfill and non-peptide bulking are the realistic risks here, so ask separately for a net content or amino acid analysis figure. See why 10 mg isn't 10 mg.

3. Third-party HPLC purity from a named laboratory. This platform records ipamorelin at 99.65 against a composite of 99.50, so "above 98%" describes a standard the market already clears comfortably. A vendor's own in-house document is not third-party testing; the laboratory should be named and identifiable (third-party peptide testing labs).

4. An LAL endotoxin result, because FDA named its absence specifically. The compounding submission was faulted for missing endotoxin data alongside impurities and aggregates. An absent LAL result means the batch was not tested for pyrogens rather than that it passed. See peptide endotoxin testing and the LAL assay.

5. Which form the vial holds — free base or acetate. PCAC voted on both substances separately in October 2024, and it is ipamorelin acetate that sits on the Category 2 list, added 29 September 2023. The free base is the one FDA described as poorly characterised. A listing that names neither form has not specified the substance it is selling.

6. Peptigrity coverage for that specific shop, not the compound in general. A compound-level average of 99.66% across 229 shops is a statement about the market, not about the vendor in your basket. Search the lab test database and the community-verified shop reviews for the shop itself, and treat an untested vendor as untested rather than as average.

7. The pricing reality check, and what no certificate establishes. Ipamorelin runs from a $2.00/mg low to a $6.00/mg median — a 7× spread across comparable offers — so price alone identifies neither the good nor the bad end. And a flawless CoA confirms a pentapeptide of the right mass at the stated quantity; it cannot tell you the compound works. The one published randomised trial missed its primary endpoint at p = 0.15, and NCT01280344, a 320-patient Phase 2 that completed in May 2014, has never posted results. One citation deserves naming: a paper titled "Ipamorelin for postoperative ileus: results of phase II/III trials" circulates attributed to PMID 11600700, which is actually "The role of acetylation in rDNA transcription," a 2001 molecular biology paper in Nucleic Acids Research. No phase II/III ipamorelin publication exists. If a vendor page cites it, that page was not fact-checked (red flags in peptide certificates of analysis).

Five of those six rows are about quantity, contaminants or paperwork. On a molecule with a 106-dalton floor under it, that is the correct distribution of attention — and it is the opposite of how ipamorelin is usually sold.

Where does ipamorelin rank on Peptigrity's lab test database?

Peptigrity's Purity Index records ipamorelin at 99.65 across 323 recency-weighted tests from 21 laboratories (verified August 2026), above the platform composite of 99.50. The ipamorelin compound page shows 407 total tests averaging 99.66% across 229 shops (verified August 2026), the larger figure because the index applies recency weighting and exclusions. Price data shows 63 shops in stock, a median of $6.00/mg and a low of $2.00/mg on a 10 mg vial — a 7× spread.

Publishing both figures matters more than picking the flattering one. 99.65 and 99.66% describe the same compound through two different lenses: the index weights recent tests more heavily and applies exclusions, while the compound page reports the raw average across every shop on record. Neither is wrong, and a buyer comparing a vendor's certificate against "the Peptigrity number" should know which number they are using. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

Read the purity figure for what it is. It says the material sold as ipamorelin tests as a very clean single species across 323 recency-weighted tests. It does not say the vials contained the labelled quantity, were free of pyrogens, or came from vendors who published anything at all — the platform records the tests that exist, and an untested shop generates no data rather than a low score. Individual results are searchable shop by shop, and Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), weighting community reviews and independently verified purity equally at 50% each in every trust score, with no financial relationship influencing the ranking.

The 7× price spread deserves a separate reading from the purity figure. A $2.00/mg offer and a $6.00/mg median sit inside the same nominal purity band, which means price is carrying information that purity is not — most plausibly about fill quantity, testing burden and endotoxin control, none of which appear in an HPLC percentage. Compare within a single vial size, since fixed per-vial costs push the per-milligram figure down as fill size rises, and the low here is quoted on a 10 mg vial. The blend most buyers actually reach for is tracked separately on the CJC-1295 and ipamorelin blend page, with the protocol in the CJC-1295 and ipamorelin stack guide.

The trial that would settle this is not a testing study, because the vial question is already answerable. It is the clinical study that has never been run.

Until that exists, the buying position is narrow and specific: you can verify an ipamorelin vial's identity to the dalton, you can verify its quantity and pyrogen status if the vendor tests for them, and you cannot verify that any of it produces an outcome. Those are three different questions, and only the first two have answers available at the point of purchase.

Frequently Asked Questions

What purity standard should ipamorelin meet?

This platform records ipamorelin at 99.65 across 323 recency-weighted tests from 21 laboratories, and 99.66% across 229 shops on the compound page (verified August 2026), against a platform composite of 99.50. Against a market clearing that high, "above 98%" promises less than the norm. Purity is also the wrong headline question here, since net content and endotoxin are where this compound's realistic problems sit.

How much does ipamorelin cost?

Price data shows 63 shops in stock, a median of $6.00/mg and a low of $2.00/mg on a 10 mg vial (verified August 2026) — a 7× spread across comparable offers. Compare within a single vial-size band, because fixed per-vial costs push the per-milligram figure down as fill size rises. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

Can ipamorelin be compounded legally?

No. FDA's Pharmacy Compounding Advisory Committee voted 0 in favour, 12 against, with 1 abstention on both the free base and the acetate in October 2024. Ipamorelin acetate remains on the Category 2 significant-safety-risk list, added 29 September 2023 and still current as of 22 April 2026. It is also prohibited in sport at all times under WADA S2.2.4.

How do I know the vial contains ipamorelin?

Mass spectrometry at 711.9 Da, or 711.3857 monoisotopic. Ipamorelin sits 106 to 175 daltons below GHRP-2, GHRP-6 and hexarelin, and it is the only member of the group without the Trp-Trp core, so any mass spectrometry run separates them without needing a high-resolution instrument. Underfill and non-peptide bulking are the more realistic problems.

Does ipamorelin work better with CJC-1295?

No controlled human trial has quantified the combination. The receptor rationale is genuine — GHRH-R and GHS-R1a are separate receptors on the same pituitary somatotrophs — but the specific synergy percentages circulating for this stack have no source, which leaves the pairing a mechanistic argument rather than a measured effect. Treat any quoted percentage from a forum post or vendor page accordingly.

Is ipamorelin really the clean one?

In pigs, yes. Raun et al. found no rise in ACTH or cortisol even at doses more than 200 times the GH-releasing dose, and no change in FSH, LH, prolactin or TSH. In humans, nobody has measured it. The familiar comparison mixes animal data for ipamorelin with human data for GHRP-2 and GHRP-6, so it is a cross-species inference rather than a measured difference. The category-level comparison is in ipamorelin vs sermorelin vs tesamorelin.

Browse the growth hormone peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the CJC-1295 and ipamorelin calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.